Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:GRFS

Grifols Q3 2026 Earnings Date & Estimates

Grifols logo
$7.24 +0.07 (+0.98%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$7.24 0.00 (-0.07%)
As of 10/14/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grifols is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. The conference call is scheduled for November 3, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Grifols in Q3 2026

Grifols is expected to post earnings of $0.3202 per share on revenue of $2.22 billion. Grifols has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.3202
Expected Revenue
$2.22 billion

Recent Track Record

Last Reported
Q4 2025
Last Quarter EPS
$0.3850
Last Quarter Revenue
$2.32 billion
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Grifols Q3 2026 Earnings FAQ

Grifols (NASDAQ:GRFS) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Grifols' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Grifols to post earnings of $0.3202 per share for Q3 2026.

The consensus revenue estimate for Grifols is $2.22 billion for Q3 2026.

Grifols Earnings Headlines

BridgeBio Pharma (NASDAQ:BBIO) versus Grifols (NASDAQ:GRFS) Head-To-Head Analysis
October 12 at 5:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109989
Grifols (NASDAQ:GRFS) Stock Rating Cut to "Hold" at Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104277
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
 |  Stansberry Research (Ad)
Are options traders betting on a big move in Grifols stock?
October 8, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/are-options-traders-betting-on-a-big-move-in-grifols-stock/ar-AA2dL4BR
Grifols says Canada plasma license suspension has no impact
September 24, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/grifols-says-canada-plasma-license-suspension-has-no-impact-2026-09-24/
GRFS - Grifols, S.A.
September 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/GRFS/dividends/dividend-safety
See More Grifols Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grifols? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grifols and other key companies, straight to your email.

About Grifols

Grifols (NASDAQ:GRFS) S.A. is a global healthcare company based in Barcelona, Spain, and is listed on Nasdaq under the symbol GRFS. Founded in 1909, the company is primarily focused on developing, manufacturing and supplying plasma-derived medicines and other healthcare products.

Its principal therapies include immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors, which are used to treat immune deficiencies, respiratory disorders, bleeding conditions and other serious diseases. Grifols operates a network of plasma donation centers, mainly in the United States and Europe, to collect the source plasma used in its medicines.

Grifols also provides diagnostic solutions, including instruments and reagents used in blood typing, transfusion medicine and laboratory testing. In addition, the company offers hospital pharmacy products and services. Its operations and products serve healthcare providers and patients in numerous markets across North America, Europe and other international regions.

View Grifols Profile
Earnings Tools